Avondale Partners Boosts Price Target on Body Central Acquisition (BODY)
Analysts at Avondale Partners boosted their price target on shares of Body Central Acquisition (NASDAQ: BODY) from $34.00 to $37.00 in a research report issued to clients and investors on Tuesday. The firm currently has a “market perform” rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at Piper Jaffray (NYSE: PJC) raised their price target on shares of Body Central Acquisition to $30.00 in a research note to investors on Friday, March 9th. Separately, analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Body Central Acquisition to $35.00 in a research note to investors on Thursday, March 8th. Finally, analysts at Oppenheimer (NYSE: OPY) raised their price target on shares of Body Central Acquisition to $31.00 in a research note to investors on Tuesday, February 14th.
Body Central Acquisition traded down 0.07% on Tuesday, hitting $14.92. Body Central Acquisition has a 1-year low of $14.25 and a 1-year high of $30.88. The company has a market cap of $240.6 million and a price-to-earnings ratio of 12.03.
Body Central Acquisition last released its earnings data on Thursday, May 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.36. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. Analysts expect that Body Central Acquisition will post $0.23 EPS next quarter.
Body Central Corp. is a specialty retailer of young women’s apparel and accessories operating retail stores in the South, Mid-Atlantic and Midwest regions of the United States.